Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effect of Dual-Task Training and Cognitive Rehabilitation in Individuals With Multiple Sclerosis.

NCT06949696 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-04-20
Last updated
2025-04-29

Condition(s) studied

Multiple Sclerosis

Investigational drug(s) / intervention(s)

Dual Task TrainingCognitive RehabilitationConventionel Physiotherapy

Dual Task Training: In dual task training, patients will be given cognitive exercises such as counting backwards from 100 by 3, counting the names of cities, girls and boys while walking.

Cognitive Rehabilitation: In cognitive rehabilitation, patients will be given paper-and-pencil activities and exercises to find the difference between two pictures.

Conventionel Physiotherapy: In conventionel physiotherapy, patients will be given posture exercises for balance and strengthening.

Study summary

The purpose of this study is to examine the effects of dual-task training and cognitive rehabilitation on gait, balance, fatigue and cognitive performance in individuals with multiple sclerosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Definite MS diagnosis by a neurologist * Can walk independently * Expanded Disability Status Scale (EDSS) score below 5 * Has not had an attack in the last 3 months, has been medically stable for 6 months * Has not received a regular physiotherapy program in the last 6 months volunteer Exclusion Criteria: * Scoring 26 or below on the Montreal Cognitive Assessment Scale (MoCA) * Having systemic, orthopedic and neurological problems that may affect walking and balance in the assessments * Having additional psychiatric disorders

Primary outcome measure(s)

  • Dynamic Gait Index (DGI) — a year
    DGI is a test that measures the capacity to adapt to changes in walking.It evaluates a total of 8 parameters over 24 points. Values of 19 points and below define the presence of a fall risk.

Trial sites (1)

FacilityCityRegionStatus
Mersin University Mersin Turkey (Türkiye) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06949696 on ClinicalTrials.gov ↗ ← All trials in Turkey